ASCO 2025
ASCO 2025
Advertisement
Laura LitwinEGFR+ NSCLC | June 16, 2025
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
Read More
Cheryl Czerlanis, MDASCO 2025 | June 13, 2025
Cheryl Czerlanis, MD, shares insights from her ASCO 2025 presentation on the topic.
Molly Li, MBBSASCO 2025 | June 12, 2025
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
Sophie Poznanski, PhDASCO 2025 | June 10, 2025
Sophie Poznanski, PhD, shares insights from her ASCO 2025 presentation on the multifunctional antibody modality.
Matthew Smeltzer, PhDASCO 2025 | June 9, 2025
The study compared results from North America with global results by high-income and low- or middle-income countries.
Cecilia BrownASCO 2025 | June 6, 2025
Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Cheryl Czerlanis, MDASCO 2025 | June 5, 2025
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Lung Cancers Today EditorsConference Coverage | June 6, 2025
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Cecilia BrownASCO 2025 | June 3, 2025
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Shriya GargASCO 2025 | June 3, 2025
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MDASCO 2025 | June 6, 2025
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MDASCO 2025 | June 2, 2025
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Cecilia BrownASCO 2025 | June 2, 2025
Charles Rudin, MD, PhD, presented the data at the 2025 American Society of Clinical Oncology Annual Meeting.
Laura LitwinConference Coverage | June 2, 2025
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer W. Carlisle, MDASCO 2025 | June 2, 2025
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Lung Cancers Today EditorsASCO 2025 | June 1, 2025
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Laura LitwinASCO 2025 | June 1, 2025
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Coral Olazagasti, MDConference Coverage | June 1, 2025
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Eric Singhi, MDConference Coverage | June 1, 2025
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MDConference Coverage | June 1, 2025
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Advertisement
Advertisement
Latest News

June 17, 2025